✦ LIBER ✦

Evaluating Health-Related Quality of Life in Cancer Clinical Trials: The National Cancer Institute of Canada Clinical Trials Group Experience

✍ Scribed by David Osoba; Andrea Bezjak; Michael Brundage; Joseph Pater

Book ID: 109078737
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 80 KB
Volume: 10
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2007.00278.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical cooperative trials of the natio

Clinical cooperative trials of the national cancer institute of Canada clinical trials group breast cancer site group

✍ Kathleen I. Pritchard 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 621 KB

Completion rates in health-related quali

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group

✍ David Osoba; Benny Zee 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

The approach of the National Cancer Institute of Canada Clinical Trials Group to measuring compliance, that is, completion rates, for health-related quality of life questionnaires is presented. Completion rates can be measured at the institutional, patient, questionnaire and item levels for baseline

The Quality of Life Committee of the Cli

The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions

✍ D. Osoba 📂 Article 📅 1992 🏛 Springer Netherlands 🌐 English ⚖ 741 KB

Venous thromboembolism and nonsmall cell

Venous thromboembolism and nonsmall cell lung cancer : A pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials

✍ Lisa K. Hicks; Matthew C. Cheung; Keyue Ding; Baktiar Hasan; Lesley Seymour; Aur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

## Abstract ## BACKGROUND: Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored. ## METHODS: I

Report from a National Cancer Institute

Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials

✍ S. G. Nayfield; P. A. Ganz; C. M. Moinpour; D. F. Cella; B. J. Hailey 📂 Article 📅 1992 🏛 Springer Netherlands 🌐 English ⚖ 827 KB

Phase II study of trimetrexate in malign

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

✍ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic